Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Bruno Gallo

Neurology Miami, FL Medical Doctor

NPI 1235159393 CMS profile 192314

9090 Sw 87Th Ct, Suite 200, Miami, FL 33176

Open in the dashboard

General payments

$313,203

832 records reported · program years 2019–2025

Research payments

$4,116

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$173,315 paid to institutions, not to them · program years 2019–2022

Through program year 2025, Bruno Gallo of Miami, FL is reported in the CMS Open Payments database as having received $313,203 across 832 general payments and $4,116 in research payments paid to them. Separately, studies naming them as principal investigator received $173,315 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $29 1
2023 General $70 3
2022 General $13,350 48
2021 General $104,592 256
2020 General $73,699 230
2019 General $121,464 294
2019 Research $4,116 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Bruno Gallo
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Bruno Gallo were reported at $29. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Bruno Gallo Neurology median Middle half National median
2019 $121,464 $474 $118–$2,177 $163
2020 $73,699 $367 $82–$2,309 $114
2021 $104,592 $438 $104–$2,547 $132
2022 $13,350 $442 $103–$2,388 $149
2023 $70 $464 $119–$2,312 $160
2024 $0 $468 $119–$2,323 $164
2025 $29 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Teva Pharmaceuticals USA, Inc. $120,430 170 payments
  2. Adamas Pharmaceuticals, Inc. $82,023 164 payments
  3. ACADIA Pharmaceuticals Inc $39,865 75 payments
  4. Acorda Therapeutics, Inc $38,261 63 payments
  5. Sunovion Pharmaceuticals Inc. $17,219 50 payments
  6. Abbott Laboratories $7,440 38 payments
  7. Kyowa Kirin, Inc. $1,780 6 payments
  8. UCB, Inc. $865 39 payments
  9. Amgen Inc. $714 30 payments
  10. US WorldMeds, LLC $681 12 payments
  11. Other $3,925 185 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $191,067 100 payments
  2. Honoraria $79,370 42 payments
  3. Consulting Fee $18,079 10 payments
  4. Food and Beverage $15,728 575 payments
  5. Travel and Lodging $8,768 102 payments
  6. Education $192 3 payments
Products named General payments · program years 2019–2025
  1. AUSTEDO $120,009 152 payments
  2. GOCOVRI $82,023 164 payments
  3. INBRIJA $37,967 58 payments
  4. NUPLAZID Parkinsons Disease Psychosis $35,835 70 payments
  5. APTIOM $16,948 40 payments
  6. NUPLAZID Pdp $4,001 3 payments
  7. Infinity DBS Pulse Generators $3,478 12 payments
  8. Libra and LibraXP DBS IPG $2,901 4 payments
  9. NOURIANZ $1,780 6 payments
  10. AIMOVIG $987 43 payments
  11. Other $7,536 304 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Eli Lilly and Company $4,116 1 payment

Records

833 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record